Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with ...
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and …